Xilio Therapeutics (XLO) Assets Average (2021 - 2026)

Xilio Therapeutics has disclosed Assets Average across 6 years of filings, most recently posting $158.9 million for Q2 2026.

• In Q2 2026, Assets Average rose 33.77% year-over-year to $158.9 million; the TTM figure through Jun 2026 stood at $158.9 million (up 33.77% YoY), while the FY2025 annual figure was $112.9 million, up 71.03% from the prior year.
• Assets Average came in at $158.9 million for Q2 2026 at Xilio Therapeutics, roughly flat from $159.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $207.2 million in Q1 2022 to a low of $69.4 million in Q4 2023.
• Average Assets Average over 5 years is $122.6 million, with a median of $122.0 million recorded in 2023.
• Year-over-year, Assets Average slumped 53.21% in 2023 and jumped 97.88% in 2025.
• Over 5 years, Assets Average stood at $148.3 million in 2022, then tumbled by 53.21% to $69.4 million in 2023, then climbed by 5.02% to $72.9 million in 2024, then jumped by 97.88% to $144.2 million in 2025, then grew by 10.18% to $158.9 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $158.9 million in Q2 2026, $159.1 million in Q1 2026, and $144.2 million in Q4 2025.